Homechevron_rightNewschevron_rightMedia Releasechevron_rightVaxxas Appoints David Hoey as Company’s First CEO

Vaxxas Appoints David Hoey as Company’s First CEO

08 October 2012

Posted in — Media Release

Share

Learn More

Posted in — Media Release

Share
chevron_leftPreviosly
Smart Sparrow a winner at Tech23 2012
23 October 2012
Nextchevron_right
Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation
08 October 2012
View All

You may also like

03 August 2020

KiRA Biotech appoints Global Pharma Business Leader as Independent Board Chair

Media Release

21 October 2014

Hatchtech announces successful results from Phase 2 ovicidal study

Media Release

31 October 2013

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

Media Release

13 August 2018

OneVentures invests in regional Queensland company developing treatments for autoimmune diseases

Media Release

18 July 2016

DoseMe partners with Charm Health to improve management of high risk oncology medicines and deliver “precision medicine” to Australian cancer patients

Media Release

26 August 2014

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Awards, Media Release

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor